6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer

Inclusion Criteria:

* Histologically proven cancer of the breast,
* Mastectomy or complete tumorectomy,
* Histologically proven homolateral, axillary lymph node involvement (at least 1 N+)
* Period between surgery (second operation in case of primarily incomplete resection) and the start of chemotherapy \< 2 months,
* Biological criteria (before the first FEC cycle):

  * Neutrophils \>1.5 109 /L
  * Platelets \>100 109/L
  * Hemoglobin \>10 g/dl
  * Creatininemia \<120 mmol/1
  * Bilirubinemia \<1.5 Upper normal value
* Female patients over 18 years old
* Written and signed informed consent
* Performance Status less than or equal to 2 (WHO scale, see Annex IV)

Exclusion Criteria:

* Prior chemotherapy or radiotherapy, including neo-adjuvant treatment for cancer of the breast,
* Bilateral breast cancer or history of contralateral breast cancer
* Cardiac history: cardiac insufficiency (LVEF \<50%) or coronary decompensation
* Pregnancy and breast-feeding (effective contraception is mandatory in the case of women of child-bearing potential)
* Inflammatory breast cancer
* Distant metastasis or supraclavicular adenopathy
* Benign pathology or history of malignant pathology accompanied by a life expectancy of less than two years
* Contra-indication to Anthracyclines, Cyclophosphamide, 5FU or Taxol
* Psychiatric pathology
* Patient participating in another trial